GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01429506

CompletedPhase NA

Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes

Effect of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Bariatric Surgery Candidate, Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥27.5•HbA1c 7-10%

Primary endpoint

•Weight loss

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01429506

Org study ID922861

Timeline

Milestones

Study first posted2011-09-07estimated

Last update posted2015-10-26estimated

Study start2011-01 (month precision)

Primary completion2012-08actual (month precision)

Study completion2012-08actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Bariatric Surgery CandidateObesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

Type 2 Diabetics with

1. BMI ≥ 27.5 kg/m2

2. HbA1c 7-10%

3. Age 20-70 years

Exclusion criteria

1. Prior gastric surgery

2. Pregnancy and lactation

3. renal disease (GFR < 60 ml/min)

4. Pancreatitis

5. Symptomatic gallstone disease

6. Active malignancy

7. Secondary causes of obesity ( Cushing's syndrome, uncontrolled Hypothyroidism)

8. Severe psychiatric illness

9. Allergic reaction to exenatide

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Weight & body composition

1 endpoint

Primary/protocol endpoint

weight loss

Time frame:6 months

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint/low confidence

glycemic control

Time frame:6 months

descriptive, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.